Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety assessment of inhaled RESP301 in hospitalized adults with pulmonary tuberculosis
ISRCTN14833199Phase 2Terminated
- Sponsor
- Thirty Respiratory Limited
- Start
- May 2023
- Modality
- Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
01
Overview
Phase 2, open-label, single-arm trial of RESP301 in pulmonary tuberculosis (TB), sponsored by Thirty Respiratory Limited. Primary endpoints: Safety and tolerability: adverse events, Safety and tolerability: serious adverse events and 2 more. Started May 2023; status: terminated.
02
Drugs
RESP301
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on ISRCTN14833199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14833199.